We are actively recruiting for participation in the following trials.
- A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis (AD-VISE) View More
AD-VISE Study Poster Mar 2023 (.pdf)
- A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) View More
Atopic Dermatitis (Rocket) Study Poster Mar 2023 (.pdf)
- Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity (CARE) View More
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema View More
Hand Eczema (Delta Force) Study Poster Mar 2023 (.pdf)
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Vitiligo (Active and Stable) (Tranquillo) View More
Vitiligo Study Poster Mar 2023 (.pdf)
If you are interested in finding out more details about our ongoing studies, please fill out the form at the bottom of this page below or contact us at 416-222-2204 or by email at maryam@bnderm.com.
Ongoing studies no longer enrolling:
– Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2) View More
– Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo View More
– A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis View More
– A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis View More
– A Randomized, Double-Blind and Placebo-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis View More
– A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT) View More
– A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2) View More
– Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND) View More
– Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE) View More
– Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2) View More
– Long-Term Safety and Efficacy of BMS-986165 in Subjects with Psoriasis View More
– Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis View More
– A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE) View More